Building a Mechanistic Mathematical Model of Hepatitis C Virus Entry
Overview
Affiliations
The mechanism by which hepatitis C virus (HCV) gains entry into cells is a complex one, involving a broad range of host proteins. Entry is a critical phase of the viral lifecycle, and a potential target for therapeutic or vaccine-mediated intervention. However, the mechanics of HCV entry remain poorly understood. Here we describe a novel computational model of viral entry, encompassing the relationship between HCV and the key host receptors CD81 and SR-B1. We conduct experiments to thoroughly quantify the influence of an increase or decrease in receptor availability upon the extent of viral entry. We use these data to build and parameterise a mathematical model, which we then validate by further experiments. Our results are consistent with sequential HCV-receptor interactions, whereby initial interaction between the HCV E2 glycoprotein and SR-B1 facilitates the accumulation CD81 receptors, leading to viral entry. However, we also demonstrate that a small minority of viruses can achieve entry in the absence of SR-B1. Our model estimates the impact of the different obstacles that viruses must surmount to achieve entry; among virus particles attaching to the cell surface, around one third of viruses accumulate sufficient CD81 receptors, of which 4-8% then complete the subsequent steps to achieve productive infection. Furthermore, we make estimates of receptor stoichiometry; in excess of 10 receptors are likely to be required to achieve viral entry. Our model provides a tool to investigate the entry characteristics of HCV variants and outlines a framework for future quantitative studies of the multi-receptor dynamics of HCV entry.
An entropic safety catch controls hepatitis C virus entry and antibody resistance.
Stejskal L, Kalemera M, Lewis C, Palor M, Walker L, Daviter T Elife. 2022; 11.
PMID: 35796426 PMC: 9333995. DOI: 10.7554/eLife.71854.
Identifying cell-to-cell variability in internalization using flow cytometry.
Browning A, Ansari N, Drovandi C, Johnston A, Simpson M, Jenner A J R Soc Interface. 2022; 19(190):20220019.
PMID: 35611619 PMC: 9131125. DOI: 10.1098/rsif.2022.0019.
Olesen C, Augestad E, Troise F, Bukh J, Prentoe J PLoS Pathog. 2021; 17(7):e1009720.
PMID: 34280245 PMC: 8321405. DOI: 10.1371/journal.ppat.1009720.
Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies.
Velazquez-Moctezuma R, Augestad E, Castelli M, Olesen C, Clementi N, Clementi M Vaccines (Basel). 2021; 9(3).
PMID: 33804732 PMC: 8004074. DOI: 10.3390/vaccines9030291.
Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.
Padmanabhan P, Desikan R, Dixit N PLoS Comput Biol. 2020; 16(12):e1008461.
PMID: 33290397 PMC: 7748278. DOI: 10.1371/journal.pcbi.1008461.